Personalized Vaccine Yields Early PFS Benefit in Metastatic MSS-CRC
Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.
FDA Accepts BLA for Dato-DXd in Metastatic HR+/HER2– Breast Cancer
Data from the phase 3 TROPION-Breast01 trial support the biologics license application for datopotamab deruxtecan in hormone receptor–positive, HER2-negative breast cancer.
Selecting Observation Vs Immunotherapy in Advanced Melanoma
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.
Observing the Evolving Prostate Cancer Landscape and Hopes for the Future
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
AEs to Monitor With Enfortumab Vedotin/Pembrolizumab in Advanced Bladder Cancer
Neuropathy is an adverse effect that can occur when enfortumab veodtin is administered to patients with locally advanced or metastatic urothelial carcinoma.
Ceramic Thyroid Ablation Needle Earns Class III Certificate in China
The characteristics of rare earth ceramics may yield more consistent microwave energy penetration during the treatment of those with thyroid nodules.
Afami-cel Demonstrates Enduring Responses in Pretreated Synovial Sarcoma
Findings from the phase 2 SPEARHEAD-1 trial demonstrate how T-cell receptor therapy may effectively target solid tumors.
Achieving Health Equity in Lung Cancer Surgery
Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.
Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations
An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.
Disadvantaged Areas Have Worse Cancer Surgery Access, Mortality
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Microbiome Signature Differences May Impact Rectal Cancer Treatment Effect
Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.
Data May Provide “Framework” for Mitigating Cancer Surgery Disparities
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors
Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.
Enfortumab Vedotin Combo Earns Priority Review in China for Bladder Cancer
Data from the phase 3 EV-302 trial support an application for enfortumab vedotin plus pembrolizumab as a treatment for patients with advanced bladder cancer in China.
Adagrasib Significantly Improves PFS Vs Chemo in KRAS G12C-Mutated NSCLC
Treatment with adagrasib in the phase 3 KRYSTAL-12 trial raised no new safety signals among patients with KRAS G12C–mutated non–small cell lung cancer.
Novel CDK9 Inhibitor Yields Responses in Relapsed/Refractory AML
Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.
Investigators Will Assess NXP800 in ARID1A-Mutated Ovarian Cancer
A phase 1b evaluating NXP800 in platinum-resistant ARID1A-mutated ovarian cancer is open for enrollment in the United Kingdom and the United States.
Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer
Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.
Capivasertib Combo Receives Approval in Japan for HR+/HER2– Breast Cancer
Findings from the phase 3 CAPItello-291 trial support the approval of capivasertib/fulvestrant for patients with hormone receptor–positive, HER2-negative breast cancer in Japan.
Pembrolizumab/Chemo Earns European Approval in Resectable NSCLC
Data from the phase 3 KEYNOTE-671 trial support the European Commission’s approval of pembrolizumab plus chemotherapy for those with resectable non–small cell lung cancer.
Taplin’s Key to a Successful GU Career: “Always Finish” What You Start
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.
Revumenib Receives FDA Priority Review in R/R KMT2Ar Acute Leukemia
Data from the phase 2 AUGMENT-101 trial support the biologics license application for revumenib in patients with relapsed/refractory KMT2A-rearranged acute leukemia.
Optimizing GVHD Prophylaxis: Exploring Intermediate-Dose PTCy in Bone Marrow Transplantation for Older Patients - Insights from Dr. Mustafa Hyder, MD's Study
Dr. Mustafa Hyder spoke about the results from a phase 1/2 trial presented during the 2024 Tandem Meeting.
Fluorescence-Guided Breast Cancer Surgery Tool May Be Gamechanger
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
AI Model May Predict Toxicity Risk in Breast Cancer Surgery Populations
Investigators will assess the PRE-ACT tool’s ability to predict adverse effects such as skin and heart damage in a phase 3 trial.
Findings Ways to Embrace Work-Life Balance as a GU Oncologist
A long commute can significantly impact your work-life balance, according to Mary-Ellen Taplin, MD.
Incorporating New ASTRO Partial Breast Irradiation Guidelines Into Practice
A Miami Breast Cancer Conference presentation focused on how the new ASTRO partial breast irradiation guidelines could be incorporated into practice.
Finding Ways to Improve Outcomes in dMMR Gastroesophageal Cancer
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Ivonescimab/Chemo Shows Promising Anti-Tumor Activity in NSCLC Subsets
Intracranial disease control with Ivonescimab plus chemotherapy appears encouraging in patients with non–small cell lung cancer and brain metastases.
FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma and DLBCL
The agency submits complete response letters based on the enrollment status of confirmatory trials for odronextamab in follicular lymphoma and diffuse large B-cell lymphoma.